{
  "abstract": "Background and Importance Faricimab is a bispecific monoclonal antibody approved for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME). Unlike previous anti-VEGF agents, faricimab targets both VEGFA and Ang-2, potentially allowing longer dosing intervals and sustained efficacy. Real-world data are essential to confirm whether these benefits translate into routine clinical practice.Aim and Objectives To evaluate the real-world effectiveness of faricimab in extending treatment intervals while maintaining visual outcomes in patients with nAMD and DME treated at a tertiary hospital.Material and Methods A retrospective observational study was conducted including all patients treated with faricimab between January 2024 and March 2025. Data collected included demographics, diagnosis, previous anti-VEGF therapy, number of injections, maximum and current treatment intervals, best visual acuity with pinhole, and treatment modifications. Effectiveness was defined as the ability to maintain clinical response while extending dosing intervals. Data were obtained from Diraya and SIPCAD electronic health records.Results 83 patients (92 eyes) were included (mean age 79 years; 47.8% female). Diagnoses: 86.9% nAMD, 10.6% DME, and 2.2% macular telangiectasia. The mean number of faricimab injections was 7.6 ± 2.75. Previous treatments included aflibercept (71.7%), brolucizumab (16.3%), ranibizumab (7.6%), and 4.3% were treatment-naïve. Maximum treatment intervals achieved were 4 weeks (13%), 6 weeks (10.9%), 8 weeks (31.5%), 12 weeks (32.6%), and 16 weeks (11.9%). Compared with prior therapy, 67.4% of eyes achieved longer intervals. At the time of analysis, 48.9% maintained their maximum extension, whereas 50% required shortening. Mean visual acuity with pinhole was 0.39. Treatment was discontinued in 34.8% (62.5% switched to aflibercept 8 mg, 6.3% to Ozurdex, and 31.3% discontinued therapy). Overall, 65.2% continued faricimab with a mean interval of 9.2 ± 3.0 weeks.Conclusion and Relevance More than half of the treated eyes achieved longer treatment intervals than with previous anti-VEGF therapies, indicating that faricimab is effective for individualised dosing in real-world settings. However, about half of the patients could not maintain the maximum interval achieved, highlighting the need for close monitoring and individualised retreatment strategies.Conflict of Interest No conflict of interest",
  "authors": [
    {
      "affiliations": [
        "Hospital Universitario Puerta Del Mar, Hospital Pharmacy, Cádiz, Spain"
      ],
      "name": "MDA Morillo"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerta Del Mar, Hospital Pharmacy, Cádiz, Spain"
      ],
      "name": "I Sánchez Lobón"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerta Del Mar, Ophthalmology, Cádiz, Spain"
      ],
      "name": "J García Fernández"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerta Del Mar, Hospital Pharmacy, Cádiz, Spain"
      ],
      "name": "C Mora Herrera"
    },
    {
      "affiliations": [
        "Hospital Universitario Puerta Del Mar, Ophthalmology, Cádiz, Spain"
      ],
      "name": "L Rodríguez García"
    }
  ],
  "title": "4CPS-077 Effectiveness of faricimab treatment: real-world study in a tertiary hospital",
  "uid": "ebaebf2a-5642-52c5-9e5f-8d829c72b352"
}